[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543224":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":82,"collaborators":7,"id":84,"slug":7,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":7,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":7,"briefSummary":98,"conditions":99,"keywords":106,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Pfizer","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[18,30,37,46,55,61,67,73],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Kaohsiung Medical University Hospital","NOT_YET_RECRUITING","Kaohsiung City","807377","Taiwan",{"type":25,"coordinates":26},"Point",[27,28],120.31333,22.61626,{"lat":28,"lon":27},{"facility":31,"status":32,"city":21,"state":7,"zip":33,"country":23,"cosmosGeoPoint":34,"geoPoint":36,"contacts":7},"Chang Gung Memorial Hospital at Kaohsiung","RECRUITING","83301",{"type":25,"coordinates":35},[27,28],{"lat":28,"lon":27},{"facility":38,"status":20,"city":39,"state":7,"zip":40,"country":23,"cosmosGeoPoint":41,"geoPoint":45,"contacts":7},"Taipei Medical University - Shuang Ho Hospital","New Taipei City","23561",{"type":25,"coordinates":42},[43,44],121.45703,25.06199,{"lat":44,"lon":43},{"facility":47,"status":32,"city":48,"state":7,"zip":49,"country":23,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"NTUH","Taipei","100",{"type":25,"coordinates":51},[52,53],121.52639,25.05306,{"lat":53,"lon":52},{"facility":56,"status":20,"city":48,"state":7,"zip":57,"country":23,"cosmosGeoPoint":58,"geoPoint":60,"contacts":7},"MacKay Memorial Hospital","10449",{"type":25,"coordinates":59},[52,53],{"lat":53,"lon":52},{"facility":62,"status":20,"city":48,"state":7,"zip":63,"country":23,"cosmosGeoPoint":64,"geoPoint":66,"contacts":7},"Taipei Veterans General Hospital","11217",{"type":25,"coordinates":65},[52,53],{"lat":53,"lon":52},{"facility":68,"status":20,"city":48,"state":7,"zip":69,"country":23,"cosmosGeoPoint":70,"geoPoint":72,"contacts":7},"Tri-Service General Hospital","11490, R.O.C.",{"type":25,"coordinates":71},[52,53],{"lat":53,"lon":52},{"facility":74,"status":20,"city":75,"state":7,"zip":76,"country":23,"cosmosGeoPoint":77,"geoPoint":81,"contacts":7},"Chang Gung Hospital Linkou","Taoyuan","333",{"type":25,"coordinates":78},[79,80],121.29696,24.99368,{"lat":80,"lon":79},{"type":83,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100543224",false,"NCT06353087","Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)","The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib","ATTRACT","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Patients aged ≥12 years\n2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician\n3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions\n4. Evidence of a personally signed and dated informed consent\u002Fassent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Any prior use of abrocitinib\n2. Simultaneous participation in a study that includes administration of any investigational drug or procedure","ALL","12 Years",{"count":94,"type":95},200,"ESTIMATED","12 Months","OBSERVATIONAL","This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.",[100,101,102,103,104,105],"Dermatitis, Atopic","Dermatitis","Eczema","Skin Diseases","Immune System Diseases","Janus Kinase Inhibitors",[107,108,109,110,111,23],"Atopic Dermatitis","Abrocitinib","JAK inhibitors","Real world","Registry","2025-09-02",{"date":114,"type":115},"2025-09-03","ACTUAL",{"date":117,"type":115},"2024-07-01",{"date":119,"type":95},"2026-05-15",{"name":5,"class":6},8]